News

Filter by Category
Filter by Year

Highly Accelerated Inverse Electron-Demand Cycloaddition of Electron-Deficient Azides with Aliphatic Cyclooctynes

Strain-promoted azide–alkyne cycloaddition (SPAAC) as a conjugation tool has found broad application in material sciences, chemical biology and even in vivo use. However, despite tremendous effort, SPAAC remains fairly slow (0.2–0.5M1 s1) and efforts to increase reaction rates by tailoring of cyclooctyne structure have suffered from a poor trade-off between cyclooctyne reactivity and stability.We here wish to report tremendous acceleration of strain-promoted cycloaddition of an aliphatic cyclooctyne (bicyclo[6.1.0]non-4-yne, BCN) with electron-deficient aryl azides, with reaction rate constants reaching 2.0–2.9M1 s1.  A remarkable difference in rate constants of aliphatic cyclooctynes versus benzoannulated cyclooctynes is noted, enabling a next level of orthogonality by a judicious choice of azide–cyclooctyne combinations, which is inter alia applied in one-pot three-component protein labelling. The pivotal role of azide electronegativity is explained by density-functional theory calculations and electronic-structure analyses, which indicates an inverse electron-demand mechanism is operative with an aliphatic cyclooctyne.

Join Mailing List

Copyright Synaffix BV 2021. All Rights Reserved

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace® Polar Spacer

Forming an integral part of every toxSYN®

linker-payload, HydraSpace® bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace

GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect™

toxSYN® Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
toxSYN®
Linker-Payload
Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase 1 inhibitor Camptothecin-based
2. SYNeamicin D™*DNA
damaging agent
Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*Nemorubicin-based
5. SYNstatin E™Microtubule
inhibitors
Auristatin-based
6. SYNstatin F™
7. SYNtansine™ Maytansine-based

* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace®

** N-6-aminohexanoyl-maytansine (Ahx-maytansine)